Bernstein analyst Nadine Sarwat lowered the firm’s price target on Ambev (ABEV) to $2.57 from $3.08 and keeps an Outperform rating on the shares. The normalization of U.S. alcohol consumption will remain the key theme of 2025, and the firm continues to believe a return to normal lies ahead.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABEV: